BioSpace News Archive

Indaptus Therapeutics, Inc. announces the Company’s Chief Scientific Officer, Michael Newman, Ph.D., has been named chair for two of the three days of the 4th STING & TLR-Targeting Therapies Summit to be held in Boston on May 9-11, where he will also be a featured speaker.

VYNE Therapeutics Inc. announced the selection of a development candidate for its oral BD2-selective bromodomain and extra-terminal inhibitor program, VYN202, for the treatment of immuno-inflammatory conditions.

Akari Therapeutics, Plc today announced financial results and highlights for the full year ended December 31, 2022, as well as recent company updates.

Immutep Limited announces it has received regulatory approval from the Paul-Ehrlich-Institut, German Federal Institute for Vaccines and Biomedicines, to initiate INSIGHT-005, an investigator-initiated, open-label Phase I trial evaluating the safety and efficacy of eftilagimod alpha in combination with BAVENCIO® in up to 30 patients with metastatic urothelial carcinoma.

OrthoPediatrics Corp. a company focused exclusively on advancing the field of pediatric orthopedics, announced its continued support of the 2023 Pediatric Orthopaedic Society of North America annual meeting this week in Nashville, Tennessee.

Esperovax, Inc., a leading oral RNA vaccine and therapeutic technology company specializing in oral mRNA-based medicines,

Poseida Therapeutics, Inc. today announced that it will participate in the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 3:15pm PT | 6:15pm ET in Las Vegas.

Corbus Pharmaceuticals Holdings, Inc. today announced that an abstract highlighting pre-clinical data for CRB-601, its avβ8 blocking antibody, has been accepted for oral presentation in the main program of the New York Academy of Sciences’ 2023 Frontiers in Cancer Immunotherapy meeting, taking place in New York, NY May 2-4, 2023.

Initial was created to take on undruggable disease-causing proteins by discriminately intercepting their translation in the exit tunnel of the ribosome

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational IDP-126 (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) Gel with a Prescription Drug User Fee Act (PDUFA) action date of October 20, 2023.